Xinda Bio IBI112 Phase I clinical study completed the first subject's drug use.

The study (CIBI112A101) was a phase I clinical study evaluating the safety, toerability, pharmacodynamics and pharmacodynamics of single-dose subsurface injections or intravenous injections of IBI112 in healthy subjects in China.
the main purpose of the study was to evaluate the safety and tolerance of Chinese health subjects after a single dose of off-the-cortective injection or intravenous injection to IBI112.
IBI112 is an antibody of leptin-23 (IL-23), a pro-inflammatory cytokine secreted by active macrophages and dendrites.
IL-23 promotes Th17 cell amplification, and the inflammatory response caused by a variety of cytokines and coercides, such as IL-17 and IL-22 secreted by Th17 cells, is associated with a variety of autoimmune diseases.
il-23 consists of two sub-base p19 and p40, of which p40 sub-base is il-23 and IL-12.
IBI112 is a monoclonal antibody that selectively targets the p19 sub-base of IL-23 and does not target the p40 sub-base, so autoimmune diseases such as psoriasis can be treated by inhibiting the IL-23/Th17 path path, without affecting the pathogen defense and tumor immunology of IL-12 mediated.
.